Literature DB >> 31248604

Treatment of the Primary Tumor in Metastatic Hormone-sensitive Prostate Cancer: Not Yet Ready for Prime Time as the Standard of Care.

Weranja K B Ranasinghe1, Chad A Reichard2, Brian F Chapin3.   

Abstract

Retrospective studies in selected patients have demonstrated a survival benefit with prostatectomy or radiotherapy (RT) of the primary tumor in metastatic hormone-sensitive prostate cancer (mHSPC). However, there is currently not enough evidence to recommend RT to the primary tumor as the standard of care for patients treated with androgen deprivation therapy plus abiraterone or docetaxel for low-volume mHSPC.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Year:  2019        PMID： 31248604      PMCID： PMC6922301          DOI： 10.1016/j.eururo.2019.06.014

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


  15 in total

1.  Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study.

Authors:  Axel Heidenreich; David Pfister; Daniel Porres
Journal:  J Urol       Date:  2014-09-22       Impact factor: 7.450

2.  Level of evidence for promising subgroup findings in an overall non-significant trial.

Authors:  Julien Tanniou; Ingeborg van der Tweel; Steven Teerenstra; Kit Cb Roes
Journal:  Stat Methods Med Res       Date:  2014-01-20       Impact factor: 3.021

3.  Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry.

Authors:  Christian Gratzke; Jutta Engel; Christian G Stief
Journal:  Eur Urol       Date:  2014-05-10       Impact factor: 20.096

4.  Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer.

Authors:  Chad G Rusthoven; Bernard L Jones; Thomas W Flaig; E David Crawford; Matthew Koshy; David J Sher; Usama Mahmood; Ronald C Chen; Brian F Chapin; Brian D Kavanagh; Thomas J Pugh
Journal:  J Clin Oncol       Date:  2016-06-20       Impact factor: 44.544

5.  Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.

Authors:  Nicholas D James; Johann S de Bono; Melissa R Spears; Noel W Clarke; Malcolm D Mason; David P Dearnaley; Alastair W S Ritchie; Claire L Amos; Clare Gilson; Rob J Jones; David Matheson; Robin Millman; Gerhardt Attard; Simon Chowdhury; William R Cross; Silke Gillessen; Christopher C Parker; J Martin Russell; Dominik R Berthold; Chris Brawley; Fawzi Adab; San Aung; Alison J Birtle; Jo Bowen; Susannah Brock; Prabir Chakraborti; Catherine Ferguson; Joanna Gale; Emma Gray; Mohan Hingorani; Peter J Hoskin; Jason F Lester; Zafar I Malik; Fiona McKinna; Neil McPhail; Julian Money-Kyrle; Joe O'Sullivan; Omi Parikh; Andrew Protheroe; Angus Robinson; Narayanan N Srihari; Carys Thomas; John Wagstaff; James Wylie; Anjali Zarkar; Mahesh K B Parmar; Matthew R Sydes
Journal:  N Engl J Med       Date:  2017-06-03       Impact factor: 91.245

6.  Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.

Authors:  Stephen H Culp; Paul F Schellhammer; Michael B Williams
Journal:  Eur Urol       Date:  2013-11-20       Impact factor: 20.096

7.  Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study.

Authors:  Nicola Fossati; Quoc-Dien Trinh; Jesse Sammon; Akshay Sood; Alessandro Larcher; Maxine Sun; Pierre Karakiewicz; Giorgio Guazzoni; Francesco Montorsi; Alberto Briganti; Mani Menon; Firas Abdollah
Journal:  Eur Urol       Date:  2014-09-10       Impact factor: 20.096

8.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.

Authors:  Christopher J Sweeney; Yu-Hui Chen; Michael Carducci; Glenn Liu; David F Jarrard; Mario Eisenberger; Yu-Ning Wong; Noah Hahn; Manish Kohli; Matthew M Cooney; Robert Dreicer; Nicholas J Vogelzang; Joel Picus; Daniel Shevrin; Maha Hussain; Jorge A Garcia; Robert S DiPaola
Journal:  N Engl J Med       Date:  2015-08-05       Impact factor: 91.245

9.  Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.

Authors:  Karim Fizazi; NamPhuong Tran; Luis Fein; Nobuaki Matsubara; Alfredo Rodriguez-Antolin; Boris Y Alekseev; Mustafa Özgüroğlu; Dingwei Ye; Susan Feyerabend; Andrew Protheroe; Peter De Porre; Thian Kheoh; Youn C Park; Mary B Todd; Kim N Chi
Journal:  N Engl J Med       Date:  2017-06-04       Impact factor: 91.245

10.  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

Authors:  Nicholas D James; Matthew R Sydes; Noel W Clarke; Malcolm D Mason; David P Dearnaley; Melissa R Spears; Alastair W S Ritchie; Christopher C Parker; J Martin Russell; Gerhardt Attard; Johann de Bono; William Cross; Rob J Jones; George Thalmann; Claire Amos; David Matheson; Robin Millman; Mymoona Alzouebi; Sharon Beesley; Alison J Birtle; Susannah Brock; Richard Cathomas; Prabir Chakraborti; Simon Chowdhury; Audrey Cook; Tony Elliott; Joanna Gale; Stephanie Gibbs; John D Graham; John Hetherington; Robert Hughes; Robert Laing; Fiona McKinna; Duncan B McLaren; Joe M O'Sullivan; Omi Parikh; Clive Peedell; Andrew Protheroe; Angus J Robinson; Narayanan Srihari; Rajaguru Srinivasan; John Staffurth; Santhanam Sundar; Shaun Tolan; David Tsang; John Wagstaff; Mahesh K B Parmar
Journal:  Lancet       Date:  2015-12-21       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.